Multisystem ALK ‐Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review
Journal of Cutaneous Pathology · 2025
DOI: 10.1111/cup.14732 ↗At a glance
Fallbericht in Journal of Cutaneous Pathology, 2025. Written by Gregory S Phillips and 5 co-authors. Institution: Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA. Major MEDLINE topics: Anaplastic Lymphoma Kinase, Carbazoles, Piperidines, Microtubule-Associated Proteins. Cited 7 times so far (Crossref); 38 references.
Abstract (original language)
Anaplastic lymphoma kinase (ALK)‐positive histiocytosis has emerged as a clinically relevant diagnosis featuring a wide span of clinical presentations, which are unified by the presence of ALK‐positive histiocytes on histopathology and molecular drivers involving the ALK kinase gene. This report presents an adult case of multisystem ALK‐positive histiocytosis with xanthogranuloma‐like features on histopathology that was responsive to ALK inhibition, and includes a review of ALK‐positive histiocytoses with cutaneous involvement reported in the literature. A 56‐year‐old male developed a widespread eruption of red‐brown papules on the face, trunk, and upper extremities. Histopathological evaluation revealed a well‐circumscribed, nodular dermal infiltrate of epithelioid histiocytes with Touton giant cells, rare bizarre multinucleated cells, and focal emperipolesis. The lesional cells were positive for CD68 and ALK1 immunohistochemical stains, and negative for CD1a. Next‐generation sequencing identified a DCTN1::ALK fusion. On imaging, he was found to have bone, lung, soft tissue, and salivary gland involvement. ALK inhibition was initiated with alectinib, resulting in rapid improvement of cutaneous lesions and eventual complete resolution of abnormal imaging findings, which was sustained at 24 months of follow‐up. This case adds to the spectrum of ALK‐positive histiocytoses and further demonstrates the positive response with targeted therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA.
- Aspen Mountain Dermatology, Bend, Oregon, USA.
- St. Charles Health System, Bend, Oregon, USA.
- Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID profiles: Gregory S Phillips
Cite
APA
Phillips, G. S., Knapp, M., Olsen, K. C., Martin, W., Hayes-Lattin, B., & Chung, J. (2025). Multisystem ALK ‐Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14732
Vancouver
Phillips GS, Knapp M, Olsen KC, Martin W, Hayes-Lattin B, Chung J. Multisystem ALK ‐Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14732
BibTeX
@article{Phillips2025,
author = {Phillips, Gregory S and Knapp, Maxwell and Olsen, Keith C and Martin, William and Hayes-Lattin, Brandon and Chung, Jina},
title = {Multisystem ALK ‐Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review},
journal = {Journal of Cutaneous Pathology},
year = {2025},
doi = {10.1111/cup.14732}
}
EUVIMED